このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aqua Bio Technology 将来の成長

Future 基準チェック /06

現在、 Aqua Bio Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Chemicals 収益成長	51.1%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Jan 20

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Dec 30

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Aqua Bio Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OB:ABTEC - アナリストの将来予測と過去の財務データ ( )NOK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2023	14	-2	-10	-10	N/A
3/31/2023	10	-10	-13	-13	N/A
12/31/2022	7	-19	-15	-15	N/A
9/30/2022	4	-20	-18	-18	N/A
6/30/2022	2	-22	-20	-20	N/A
3/31/2022	2	-21	-22	-20	N/A
12/31/2021	2	-19	-25	-21	N/A
9/30/2021	2	-18	-23	-19	N/A
6/30/2021	1	-18	-22	-18	N/A
3/31/2021	1	-16	-18	-16	N/A
12/31/2020	1	-15	-13	-13	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-11	-14	-14	N/A
3/31/2020	1	-12	-16	-16	N/A
12/31/2019	1	-13	-17	-17	N/A
9/30/2019	1	-26	-18	-18	N/A
6/30/2019	1	-38	-18	-18	N/A
3/31/2019	1	-38	-18	-18	N/A
12/31/2018	1	-38	-18	-17	N/A
9/30/2018	1	-30	-17	-17	N/A
6/30/2018	2	-22	-17	-16	N/A
3/31/2018	6	-19	-17	-16	N/A
12/31/2017	10	-16	-17	-16	N/A
9/30/2017	22	-6	-1	0	N/A
6/30/2017	33	-4	4	5	N/A
3/31/2017	41	-3	N/A	13	N/A
12/31/2016	49	1	N/A	26	N/A
9/30/2016	47	5	N/A	20	N/A
6/30/2016	46	13	N/A	24	N/A
3/31/2016	42	17	N/A	25	N/A
12/31/2015	39	17	N/A	22	N/A
9/30/2015	34	11	N/A	18	N/A
6/30/2015	30	10	N/A	14	N/A
3/31/2015	26	5	N/A	11	N/A
12/31/2014	22	1	N/A	7	N/A
9/30/2014	21	-2	N/A	4	N/A
6/30/2014	19	-4	N/A	4	N/A
3/31/2014	21	0	N/A	11	N/A
12/31/2013	23	3	N/A	6	N/A
9/30/2013	20	2	N/A	5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABTECの予測収益成長が貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ABTECの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ABTECの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ABTECの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ABTECの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABTECの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aqua Bio Technology 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023

Recent updates

New major risk - Share price stability

Aqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025

New minor risk - Financial data availability

Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.

Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.

New major risk - Shareholder dilution

Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic Formulations

New minor risk - Shareholder dilution

Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in funding

New major risk - Share price stability

Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in funding

Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.

Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023

Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023

No independent directors

Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

No independent directors

Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UK

Chief Executive Officer recently bought kr55k worth of stock

Insider recently sold kr1.9m worth of stock

Director recently bought kr57m worth of stock

Aqua Bio Technology ASA Announces Strategic Partnership with DCP Dermoscience

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and Australia

Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma Aps

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty AS

Aqua Bio Technology ASA to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr9.20

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Director recently bought kr141k worth of stock

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & Vitality

Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md Platform

Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP.

Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and Australia

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic Beauty

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.

New 90-day high - kr8.35

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘